Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Optimized Novel Wireless Assessment of Respiratory and Circulatory Dirstress - Alarm Validation (ONWARD - AV)

10. juni 2026 oppdatert av: Eske Kvanner Aasvang

Validation of the Accuracy and Relevance of Continuous Vital Sign Monitoring Using an AI-algorithm in Hospitalized Patients

The ONWARD study evaluates user experiences from continuous vital sign monitoring alarms sent to the clinical staff in case of deviating vital signs at the general hospital ward. User experiences are evaluated though a 5-point likert questionnaire.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

The ONWARD study evaluates user experiences from continuous vital sign monitoring alarms sent to the clinical staff in case of deviating vital signs at the general hospital ward. User experiences are evaluated though a 5-point likert questionnaire.

The study will focus on adult, hospitalized patients who are monitored at the general hospital ward with continuous, real-time vital sign monitoring combined with the WARD-CSS (WARD clinical support system) that relays alerts to the clinical staff in case of significant deviations. The evaluation focus on the user perceived relevance and usefulness of the alerts generated by the system which includes a proprietary novel alerts logic. Specifically, investigators aim to assess how users evaluate the clinical relevance of triggered change-based alerts and the helpfulness of the accompanying alert descriptions.

During monitoring, the app will be used according to the intended use and additionally two questions will be prompted if alerts are sent.

Patients monitored will have an expected length of stay at the hospital, which supports at least one day of continuous monitoring. Readings from the WARD-CSS is not blinded for treating staff to get feedback on the use of the application. This study will include up to 100 patients.

An alerting feedback questionnaire will be constructed as simple feedback buttons/sliders, prompted after an alert is 'accepted' in the app. The feedback buttons will only be prompted for a representative proportion of the alerts. This will be done at random based on the alert frequencies determined in the retrospective analysis. This way, a close to equal amount of feedback responses will be prompted and obtained for different alert types with different occurrences. The feedback will be linked to the alert in the app, such that feedback can be submitted at any point in time, thus not disturbing the nurse while medical intervention is provided.

The feedback will be constructed with the following two interactions for the clinical staff.

  • Alert relevance in relation to deterioration of the patient (5-point Likert scale).
  • Relevance of the description following alerts in relation to the helpfulness in the patient assessment/care (5-point Likert scale)

Studietype

Intervensjonell

Registrering (Antatt)

100

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Copenhagen, Danmark, 2100
        • Rigshospitalet
      • Copenhagen, Danmark, 2400
        • Bispebjerg hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion criteria:

Patients can be included if they meet all the following criteria:

  • Age ≥ 18 years
  • Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration.
  • Expected admission for more than 24 hours to a general ward.

Exclusion criteria:

Patients are excluded if they meet any of the following criteria:

  • Having implanted electronic devices (such as pacemaker or Implantable Cardioverter Defibrillator (ICD) device).
  • Known pregnancy or breastfeeding
  • Inability to give informed consent.
  • The participant expected not to cooperate with study procedures.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Adult, hospitalized patients who are monitored for vital signs in the general wards
The intervention involves continuous, real-time vital sign monitoring using sensors to measure vital signs combined with WARD-CSS and novel algorithms designed to detect clinically relevant deviations in the vital signs.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relevance of alerts
Tidsramme: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.

The staff evaluated relevance of alerts triggered during continuous vital signs monitoring

Evaluated by 5-point Likert scale:

1. Not relevant 2 Slightly relevant 3 Moderately relevant 4 Relevant 5 Highly Relevant

Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Relevance of the description
Tidsramme: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.

Relevance of the description following alerts in relation to the helpfulness in the patient assessment/care

Evaluated by 5-point Likert scale:

  1. Strongly Disagree
  2. Disagree 3- Undecided

4 Agree 5 Strongly Agree

Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Alert rate
Tidsramme: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
Total alert rate, including false alert rate, of the WARD-CSS.
Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
Postoperative complications
Tidsramme: 30 days
Postoperative complications, defined by internationally agreed criteria
30 days
Heart rate (measured in beats per minute (BPM))
Tidsramme: 7 days
Collected continuously
7 days
SpO2 (blood oxygen saturation, measured in percentage)
Tidsramme: 7 days
Collected continuously
7 days
Blood pressure (measured in mmHg)
Tidsramme: 7 days
Collected continuously
7 days
Respiration Rate (measured in BrPM)
Tidsramme: 7 days
Collected continuously
7 days
Pulse (measured in BPM)
Tidsramme: 7 days
Peripheral pulse - Collected continuously
7 days
Temperature (measured in degrees Celcius)
Tidsramme: 7 days
Collected continuously
7 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

28. mai 2026

Primær fullføring (Antatt)

30. september 2026

Studiet fullført (Antatt)

31. mars 2028

Datoer for studieregistrering

Først innsendt

1. juni 2026

Først innsendt som oppfylte QC-kriteriene

10. juni 2026

Først lagt ut (Faktiske)

16. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2502107 (MREC)
  • 2025071987 (Annen identifikator: DMA)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Data access can be discussed upon request

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere